600789 鲁抗医药
2025/03 - 三个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入1,673,700-6.95%6,233,0906,146,7215,621,4424,923,784
减:营业总成本1,603,576-7.75%5,966,9795,907,6645,455,3694,793,389
    其中:营业成本1,327,190-2.93%4,739,4694,631,2684,373,9623,746,105
               财务费用14,047-20.12%53,59066,63978,20168,159
               资产减值损失16,324809.94%(66,943)(54,682)(41,938)(30,942)
公允价值变动收益----30(69)52113
投资收益(1,299)-26.73%(7,591)(7,134)(6,582)(3,296)
    其中:对联营企业和合营企业的投资收益(1,299)-26.73%(7,673)(7,169)(6,611)(3,295)
营业利润85,8626.55%436,190272,133148,774116,019
利润总额86,0306.32%433,901272,975150,095113,579
减:所得税费用3,681-63.02%25,55416,1886,98023,687
净利润82,34916.04%408,348256,787143,11589,891
减:非控股权益3,7512.52%13,73210,6155,102793
股东净利润78,59816.77%394,616246,172138,01389,099

市场价值指针
每股收益 (元) *0.09012.50%0.4400.2800.1600.100
每股派息 (元) *----0.1320.0900.0550.050
每股净资产 (元) *4.4468.28%4.3604.0313.7853.695
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容